1. Epigenetics Protein Tyrosine Kinase/RTK JAK/STAT Signaling Stem Cell/Wnt
  2. JAK STAT
  3. JAK2-IN-15

JAK2-IN-15 是一种口服有效的强效选择性 JAK2 抑制剂 (IC50 = 1.17 nM)。JAK2-IN-15 可抑制 AK2-STAT 信号通路。在重组人促红素 (rhEPO) 诱导的小鼠模型中,JAK2-IN-15 可显著改善血细胞比容和脾肿大等关键病理指标。JAK2-IN-15 可用于真性红细胞增多症 (PV) 的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK2-IN-15

JAK2-IN-15 Chemical Structure

CAS No. : 3094174-82-7

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

查看 JAK 亚型特异性产品:

查看 STAT 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

JAK2-IN-15 is an orally active, potent, selective JAK2 inhibitor (IC50 = 1.17 nM). JAK2-IN-15 can inhibit the AK2-STAT signaling pathway. JAK2-IN-15 significantly improves key pathological indicators such as hematocrit and splenomegaly in an Epoetin beta (HY-114134) (rhEPO)-induced mouse model. JAK2-IN-15 can be used for the study of Polycythemia Vera (PV)[1].

IC50 & Target

JAK2

1.17 nM (IC50)

体外研究
(In Vitro)

JAK2-IN-15 (Compound 2) 表现出强效的 JAK2 抑制活性 (IC50 = 1.17 nM)[1]
JAK2-IN-15 (72 小时) 能有效抑制携带 JAK2V617F 突变的 HEL (IC50 = 1.88 μM) 和 SET-2 (IC50 = 9.56 μM) 细胞的增殖[1]
JAK2-IN-15 (0.3-10 μM,72 小时) 通过剂量依赖性地抑制 JAK2-STAT 信号通路,对携带 JAK2V617F 突变的 HEL 和 SET-2 细胞表现出显著的抗增殖活性[1]
JAK2-IN-15 (100 μM) 仅抑制 17 种野生型激酶,表现出很强的选择性[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: HEL 92.1.7 cells, SET-2
Concentration: 0.3 μM, 1 μM, 3 μM, 10 μM
Incubation Time: 4 h
Result: Effectively inhibited phosphorylation of JAK2 (Y1007/8 site), STAT3, STAT5, AKT and ERK.
体内研究
(In Vivo)

JAK2-IN-15 (Compound 2) (25-75 mg/kg,口服,每日一次,持续 4 天) 在 rhEPO 诱导的红细胞增多症小鼠模型中表现出显著的治疗效果,剂量依赖性地抑制脾肿大、血细胞比容和网织红细胞增多,且具有良好的安全性[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A model of polycythemia and splenomegaly was created using female BALB/c mice (8-10 weeks old, weighing 17-20 g) by subcutaneous injection of 10 units of recombinant human erythropoietin (rhEPO) daily for 4 consecutive days[1].
Dosage: 25 mg/kg, 50 mg/kg, 75 mg/kg
Administration: P.o., once daily for 4 days
Result: Spleen weight decreased.
Dose-dependent inhibition of hematocrit.
Reduction of rhEPO-induced reticulocyte proliferation.
Inhibition of Ter119/CD71 erythroblast expansion in the spleen and bone marrow.
No significant effect on white blood cell count or body weight.
分子量

517.62

Formula

C29H35N5O4

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
JAK2-IN-15
目录号:
HY-178936
需求量: